Abstract library

10 results for "BRAFV600E".
#131 Efficacy and safety results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR
Introduction: Pasireotide, a multi-receptor targeted somatostatin analogue, has 30-, 5- and 39-fold greater affinity for sst1,3 and sst5 receptors, respectively, and a slightly lower affinity for sst2, than octreotide. Because of this multi-receptor binding profile, pasireotide may be effective in controlling symptoms of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors (NETs) who are no longer responsive to currently available somatostatin analogues.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Larry K Kvols
#389 Czech Neuroendocrine Tumor Registry - 28 Months Results
Introduction: Cooperative Group for NET was established on 22 April 2008. It continues with the practices of the Czech Carcinoid Group since 1998. The real incidence of neuroendocrine tumors is unknown. The majority remain undiagnosed. Therefore, the Czech Registry started in October 2009 to identify NET patients and to facilitate the diagnosis and therapy in centers with NET experts.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Jaroslava Barkmanova
#965 Metabonomic Profiling: A Novel Approach in Neuroendocrine Neoplasias
Introduction: There is a substantial unmet need for novel biomarkers for neuroendocrine neoplasms (NEN).
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Professor Beatriz Jiminez
Keywords: Metabonomics, NEN
#1227 Molecular Profiling of Small Intestinal Neuroendocrine Tumours (SINETs)
Introduction: Aberrant DNA methylation plays an role in the pathogenesis of many cancers, however little is known about its role in SINET development.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Anna Karpathakis
#1493 Efficacy and Tolerance of a Simplified Combination of Streptozotocine and Epi-adriamycine in Metastatic Foregut Neuroendocrine Tumor (NET). A Pilot Study
Introduction: Since more than 30 years the combination of Adriamycine (A) and Streptozotocine (STZ) is considered as one of the standard chemotherapy regimens (Moertel et al, N Engl J Med 1992, 326 : 519-23) for patients with aggressive grade 2 metastatic pancreatic NET (PNET).
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: MD Celine Lepère
Authors: Hirsch L, Lepère C, Zaanan A, Landi B, ...
#1711 Survival Analysis of Combined Therapy with 177Lu-Octreotate and Somatostatin Analogues in Advanced Metastatic Neuroendocrine Tumours
Introduction: Although somatostatin analogues (SSA) and peptide receptor radionuclide therapy with 177Lu-octreotate (PRRT) are validated therapies in patients with advanced metastatic neuroendocrine tumours, it is still unclear if the combined therapy with PRRT and SSA can provide a prolonged survival compared to patients treated with PRRT alone.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr. Anna Yordanova
#2123 Large Cell Neuroendocrine Carcinoma (LCNEC) Associated with a Dysplastic Sessile Serrated Lesion (SSL) and Deficient Mismatch Repair (MMR) Protein: A Case Report.
Introduction: Colorectal poorly differentiated neuroendocrine carcinomas (NECs) are rare, but extremely aggressive. The mechanisms of their carcinogenesis and aggressiveness are still largely unknown. Recently Nobuyoshi Takizawa showed that the molecular features of colorectal NECs are similar to those of adenocarcinoma and not to those of NETs and they were more evident in small cell NECs than in large cell NECs. This is supported by combined cases with conventional adenoma/adenocarcinoma and NECs. Stelow et al showed that DNA mismatch repair proteins were intact in 14/15 colorectal small cell NECs. Two cases of LCNECs arising from SSL have been reported so far in the literature.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Dr Tu Vinh Luong
Authors: Luong T V, Nisa Z, ...
#2165 A Pilot Study of the Cyclin Dependent Kinases 4, 6 Inhibitor Ribociclib in Patients with Foregut Neuroendocrine Tumors
Introduction: Increased cyclin dependent kinases 4, 6 (cdk 4/6) activity is noted in the majority of well differentiated foregut neuroendocrine tumors (fNETs) due to mutations in MENIN and other aberrations. These tumors also have preserved Rb function making cdk 4/6 inhibitors attractive agents for therapy.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Assistant Profes Arvind Dasari
#2211 Clinicopathologic Characteristics of Chinese Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: Results of a Nation-Wide Retrospective Epidemiology Study
Introduction: he rare incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) has contributed to a paucity of large epidemiologic studies of patients with this condition, especially in China.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Pei Yu
Authors: Yu P, Chi Y, Shi S, Chen Y, ...
#2247 Efficacy of Oral Chemotherapy with Capecitabine and Temozolomide (Captem) in Patients with Metastatic Neuroendocrine Tumors (NETS). A Single-Institution Experience
Introduction: CapTem chemotherapy regimen is a standard treatment for NETs but limited scientific data on its efficacy and tolerability are available
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Valeria Smiroldo
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.